Michigan State University · Microbiology & ImmunologyMycobacterial Drug Discovery Unit
Robert B Abramovitch · East Lansing, Michigan
Research Focus
The lab led by Robert B. Abramovitch focuses on developing new drugs to treat serious infections caused by mycobacteria, such as tuberculosis and other non-tuberculous mycobacterial infections. They are discovering potent new compounds that can effectively target these bacteria, which are often resistant to current antibiotics. This research is crucial since these infections can lead to severe health issues and are a global health concern due to rising drug resistance.
tuberculosismycobacterial infectionsdrug resistancenovel antibioticschemical biologyantimycobacterial agentsMmpL3structure-activity relationshipdrug potencycombination therapy
Research Aims
5AIM 01Develop new nitro-containing compounds to treat tuberculosis and mycobacterial infections.
AIM 02Optimize the structure and activity of existing compounds to enhance their efficacy.
AIM 03Investigate the mechanisms of resistance to new drug candidates.
AIM 04Examine the effectiveness of combination therapies against mycobacterial infections.
AIM 05Characterize MmpL3 inhibitors for potential therapeutic applications.
Skills the Lab Values
antibiotic sensitivity testingchemical synthesismurine modelshigh-throughput screeningcell culturein vivo efficacy studiespharmacokinetic studiesstructure-activity relationship analysismutant screeningcombination drug therapy
Output against the department
Publications78bottom 25% of dept.366th of 486
this lab
most publishedleast published
Citations5.7kbottom 43% of dept.278th of 486
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.